Idiopathic inflammatory myopathy: Treatment options



Idiopathic inflammatory myopathy (IIM) comprises a group of rare disorders in which there is an immune-mediated attack on skeletal muscle, the consequence of which is muscle damage and weakness in the patient. As in other inflammatory diseases, the general approach to therapy is use of immunosuppressive agents. Many options exist for IIM treatment, but therapeutic approaches are based mostly on empirical evidence and small studies, many of which are uncontrolled. Recently, new agents have been designed to target specific components of the immune response, and they offer hope for more effective or safer IIM therapy.

References and Recommended Reading

  1. 1.
    Dalakas MC: Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004, 17: 561–567.PubMedCrossRefGoogle Scholar
  2. 2.
    Baer AN: Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2006, 8: 178–187.PubMedCrossRefGoogle Scholar
  3. 3.
    Baer AN, Wortmann RL: Myotoxicity associated with lipidlowering drugs. Curr Opin Rheumatol 2007, 19: 67–73.PubMedGoogle Scholar
  4. 4.
    Levine SM: Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006, 18: 620–624.PubMedCrossRefGoogle Scholar
  5. 5.
    Hengstman GJ, van Engelen BG, van Venrooij WJ: Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004, 16: 692–699.PubMedGoogle Scholar
  6. 6.
    Rider LG, Giannini EH, Harris-Love M, et al.: Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003, 30: 603–617.PubMedGoogle Scholar
  7. 7.
    Isenberg DA, Allen E, Farewell V, et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43: 49–54.CrossRefGoogle Scholar
  8. 8.
    Oddis CV, Medsger TA: Current management of polymyositis and dermatomyositis. Drugs 1989, 37: 382–390.PubMedGoogle Scholar
  9. 9.
    Neeck G: Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann N Y Acad Sci 2002, 966: 28–38.PubMedGoogle Scholar
  10. 10.
    Joffe MM, Love LA, Leff RL, et al.: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94: 379–387.PubMedCrossRefGoogle Scholar
  11. 11.
    Dalakas M: Treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 1989, 1: 443–449.PubMedGoogle Scholar
  12. 12.
    Amato AA, Griggs RC: Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 2003, 16: 569–575.PubMedCrossRefGoogle Scholar
  13. 13.
    Nzeusseu A, Brion F, Lefebvre C, et al.: Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol 1999, 17: 441–446.PubMedGoogle Scholar
  14. 14.
    Oddis CV: Idiopathic inflammatory myopathies: a treatment update. Curr Rheumatol Rep 2003, 5: 431–436.PubMedCrossRefGoogle Scholar
  15. 15.
    Laxer RM, Stein LD, Petty RE: Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987, 30: 328–334.PubMedCrossRefGoogle Scholar
  16. 16.
    Bolosiu HD, Man L, Rednic S: The effect of methylprednisone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol 1999, 455: 349–357.PubMedGoogle Scholar
  17. 17.
    Matsubara S, Sawa Y, Takamori M, et al.: Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994, 57: 1008.PubMedCrossRefGoogle Scholar
  18. 18.
    Tymms KE, Webb J: Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985, 12: 1140–1148.PubMedGoogle Scholar
  19. 19.
    Quinn MA, Emery P: Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003, 21: S154–157.PubMedGoogle Scholar
  20. 20.
    Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349: 1526–1533.PubMedCrossRefGoogle Scholar
  21. 21.
    Arnett FC, Whelton JC, Zizic TM, Stevens MB: Methotrexate therapy in polymyositis. Ann Rheum Dis 1973, 32: 536–546.PubMedCrossRefGoogle Scholar
  22. 22.
    Metzger AL, Bohan A, Goldberg LS, et al.: Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974, 81: 182–189.PubMedGoogle Scholar
  23. 23.
    Vencovsky J, Jarosova K, Machacek S, et al.: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29: 95–102.PubMedCrossRefGoogle Scholar
  24. 24.
    Bunch TW, Worthington JW, Combs JJ, et al.: Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980, 92: 365–369.PubMedGoogle Scholar
  25. 25.
    Bunch TW: Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981, 24: 45–48.PubMedCrossRefGoogle Scholar
  26. 26.
    Miller J, Walsh Y, Saminaden S, et al.: Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002, 199(Suppl 1): S53.Google Scholar
  27. 27.
    Villalba L, Hicks JE, Adams EM, et al.: Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41: 392–399.PubMedCrossRefGoogle Scholar
  28. 28.
    Dalakas MC: High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003, 24(Suppl 4): S256–259.PubMedCrossRefGoogle Scholar
  29. 29.
    Cherin P, Pelletier S, Teixeira A, et al.: Results and longterm followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46: 467–474.PubMedCrossRefGoogle Scholar
  30. 30.
    Zeller V, Cohen P, Prieur AM, Guillevin L: Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 1996, 23: 1424–1427.PubMedGoogle Scholar
  31. 31.
    Jones DW, Snaith ML, Isenberg DA: Cyclosporine treatment for intractable polymyositis. Arthritis Rheum 1987, 30: 959–960.PubMedCrossRefGoogle Scholar
  32. 32.
    Qushmaq KA, Chalmers A, Esdaile JM: Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000, 27: 2855–2859.PubMedGoogle Scholar
  33. 33.
    Gelber AC, Nousari HC, Wigley FM: Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 1999, 27: 1542–1545.Google Scholar
  34. 34.
    Majithia V, Harisdangkul V: Mycophenolate mofetil (Cell-Cept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44: 386–389. (Published erratum appears in Rheumatology (Oxford) 2005, 44: 569.)CrossRefGoogle Scholar
  35. 35.
    Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142: 65–69.PubMedCrossRefGoogle Scholar
  36. 36.
    Oddis CV, Sciurba FC, Elmagd KA, Starzl TE: Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353: 1762–1763.PubMedCrossRefGoogle Scholar
  37. 37.
    Wilkes MR, Sereika SM, Fertig N, et al.: Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005, 52: 2439–2446.PubMedCrossRefGoogle Scholar
  38. 38.
    Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52: 601–607.PubMedCrossRefGoogle Scholar
  39. 39.
    Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33: 1021–1026.PubMedGoogle Scholar
  40. 40.
    Mok CC, Ho LY, To CH: Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007, 34: 1864–1868.PubMedGoogle Scholar
  41. 41.
    Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143: 763–767.PubMedCrossRefGoogle Scholar
  42. 42.
    Labioche I, Liozon E, Weschler B, et al.: Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 2004, 43: 531–532.CrossRefGoogle Scholar
  43. 43.
    Hengstman GJ, van den Hoogen FH, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50: 10–15.PubMedCrossRefGoogle Scholar
  44. 44.
    Sprott H, Glatzel M, Michel BA: Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004, 43: 524–526.CrossRefGoogle Scholar
  45. 45.
    Musial J, Undas A, Celinska-Lowenhoff M: Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 2003, 42: 1566–1568.CrossRefGoogle Scholar
  46. 46.
    Efthimiou P, Schwartzman S, Kagen LJ: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65: 1233–1236.PubMedCrossRefGoogle Scholar
  47. 47.
    Hengstman GJ, De Bleecker JL, Feist E, et al.: Open-label trial of anti-TNF-alpha in dermato-and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59: 159–163.PubMedCrossRefGoogle Scholar
  48. 48.
    Dastmalchi M, Grundtman C, Alexanderson H, et al.: A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008 (Epub ahead of print).Google Scholar
  49. 49.
    Miller FW, Leitman SF, Cronin ME, et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326: 1380–1384.PubMedGoogle Scholar
  50. 50.
    Cherin P, Auperin I, Bussel A, et al.: Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exper Rheumatol 1995, 13: 270–271.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Weill Medical CollegeCornell UniversityNew YorkUSA
  2. 2.Hospital for Special SurgeryNew YorkUSA

Personalised recommendations